Background: This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with esophageal cancer.
Introduction
Approximately 12 000 new cases of esophageal cancer are diagnosed in the USA each year [1] . At present, approximately half of those patients present with locally advanced disease that is potentially curable [1] . Unfortunately, the majority of the patients treated with either surgery and/or chemoradiotherapy relapse with systemic disease with or without local recurrence. The overall 5-year survival rate for patients with newly diagnosed esophageal cancer remains <10% [1] . The major reason for this high mortality is the presence of metastases at the time of diagnosis and the limited effectiveness of systemic therapies for esophageal cancer. In the metastatic setting, cisplatin-based combination chemotherapy has resulted in a partial response rate of 25-50% in treated patients [2, 3] . Responses are typically brief, lasting for a median of 4 months [3] . Improvement in the outcome of treatment for esophageal cancer is dependent on the development of more effective systemic therapy.
As a single agent, paclitaxel has demonstrated encouraging activity in a phase II trial of 50 patients with unresectable esophageal cancer with an objective response rate of 32% [4] . In vitro experiments demonstrate a synergic interaction in human cancer cell lines treated with paclitaxel followed by cisplatin [5] . In a phase I trial of cisplatin and paclitaxel, less myelotoxicity was seen when paclitaxel was administered first [6] . The combination of cisplatin and paclitaxel, however, resulted in significant neurotoxicity, which was the dose-limiting toxicity.
In comparison with cisplatin, carboplatin has lower incidence of neurotoxicity, and is easier to administer in an outpatient setting. Pharmacokinetic studies of paclitaxel administered with carboplatin demonstrate that area under the curve (AUC)-guided dosing can be accurately predicted by the Calvert formula [7] , allowing carboplatin to be combined at full doses with paclitaxel [8, 9] .
Based on these considerations, we conducted this phase II study to evaluate the efficacy and tolerability of the paclitaxel and carboplatin combination in patients with non-metastatic and metastatic esophageal cancer. The primary end point of this study was objective tumor response.
Materials and methods

Patient eligibility
Patients were considered eligible if they had pathologic confirmation of either squamous cell carcinoma or adenocarcinoma of the esophagus or the gastroesophageal junction. Patients were required to have a TNM stage IIA (T2N0M0) or higher. Patients were also required to have a Southwest Oncology Group (SWOG) performance status of 0-2, a life expectancy of at least 3 months, and adequate hematological, renal and hepatic function defined by the following parameters: neutrophils ≥1500/mm 3 , platelets ≥100 000/mm 3 , creatinine ≤1.5 mg/dl, total serum bilirubin ≤1.5 mg/dl and alanine aminotransferase (ALT) <2.5× the upper limit of the institutional normal range. Patients were required to have bidimesionally measurable disease. Irradiated tumors with no evidence of progression after radiation therapy were not considered measurable. Prior surgery or radiation therapy was permitted as long as the patients had recovered from these procedures. Female patients of childbearing potential must have had a negative serum pregnancy test prior to enrolment, and all fertile patients had to agree to use contraception during the study. All patients provided a signed informed consent in accordance with the Wayne State University Human Investigation Committee guidelines prior to enrolment on the study.
Patients were excluded from study participation if they had another active malignancy within the preceding year except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer. Pregnant or lactating women were excluded from the study. Additional exclusion criteria included previous chemotherapy for esophageal cancer within the preceding 6 months.
Study design and treatment plan
All treatment was delivered in the outpatient setting. Patients were premedicated with either oral or intravenous dexamethasone prior to paclitaxel. Diphenhydramine hydrochloride 50 mg intravenously (i.v.), ondansetron 16-24 mg orally and ranitidine 50 mg i.v. were given 30-60 min prior to paclitaxel. Paclitaxel infusion preceded the administration of carboplatin. The doses of paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ, USA) and carboplatin (Paraplatin; Bristol-Myers Squibb) for the first course were 200 mg/m 2 , and targeted AUC of 5 mg/h/ml (as per the Calvert formula), respectively. Cycles were to be repeated every 21 days. Dosages of paclitaxel and carboplatin were escalated to 225 mg/m 2 and an AUC 6 mg/h/ml, respectively, after the first course if the nadir granulocyte count was ≥1000/mm 3 , nadir platelet count was ≥100 000/mm 3 and there was acceptable non-hematological toxicity. Patients with non-metastatic disease were treated until best response and then received local therapy according to the investigators discretion. Local treatment could consist of chemoradiotherapy, surgery or a combination of both. Patients with non-metastatic disease were treated with curative intent. Paclitaxel dose was reduced for grade 2 or 3 neurotoxicity. Patients with grade 4 neurotoxicity were removed from the study. Doses of carboplatin and paclitaxel were attenuated for grade 3 or 4 non-hematological toxicity, a nadir granulocyte count <500/mm 3 , or platelet count <50 000/mm 3 . The initial dose reduction was 25 mg/m 2 for paclitaxel and 1 mg/h/ml of AUC for carboplatin.
If toxicity persisted, a second dose reduction of paclitaxel to 135 mg/m 2 was allowed. Once a dose had been reduced during a treatment cycle, re-escalation was not permitted during any other subsequent cycles.
A new cycle of therapy could begin if the neutrophil count was ≥1500/mm 3 , the platelet count was ≥100 000/mm 3 , and all relevant non-hematological toxicities were grade ≤2. Patients requiring a delay in therapy of >2 weeks or more than two dose reductions were removed from the study. Additionally, patients were removed from the study if any of the following occurred: disease progression, unacceptable toxicity, withdrawal of consent, or initiation of chemoradiotherapy or surgery for patients with locally advanced disease.
On-study evaluation
Standard efficacy end points of objective response, duration of response, and survival were assessed. Assessment of response was based on computed tomography. These imaging studies were performed at baseline and repeated after every two cycles of therapy. Tumor responses were categorized as complete response, partial response, disease progression or stable disease. Complete response was defined as disappearance of all measurable and evaluable disease without the appearance of any new lesions. Partial response was defined as a ≥50% reduction in the sum of the products of all measurable lesions compared with baseline measurements. Progressive disease was defined as a ≥25% increase in the sum of the products of any measurable lesion relative to either the baseline or the maximal response, or the appearance of any new lesion. Stable disease was defined as changes in tumor size that did not meet criteria for either progressive disease, or complete or partial response. Objective responses required one confirmatory follow-up evaluation at least 3 weeks after the initial response was determined. Duration of response was defined as the time from partial response until first evidence of relapse or death from any cause. Duration of response was censored for patients who were removed from the study or received antitumor therapy other than carboplatin and paclitaxel including chemoradiotherapy or surgery. Progression-free survival (or time to progression) was defined as the time from treatment start until disease progression or death from any cause. For patients still progressionfree at last tumor assessment, progression-free survival was censored as of that date. Overall survival was defined as the time from treatment start until death from any cause. For patients still alive at last follow-up for vital status, overall survival was censored as of that date. Toxicities were evaluated at a minimum on day 1 of each cycle and graded according to WHO toxicity criteria.
Statistical methods
This phase II trial was planned with a Fleming two-stage design [10] . We wished to distinguish these regions of the true, unknown response rate: ≤0.40 versus ≥0.60. The two-stage design called for a maximum of 40 responseevaluable patients, 20 each in stage 1 and stage 2, and had type I error of 0.04 and power of 0.78. Nine to 12 (complete or partial) responders among the first 20 response-evaluable patients were needed to justify beginning stage 2, and nine responses were observed. Accrual slowed considerably during the later part of the trial such that it became necessary to close the trial because of it, with a total of 35 eligible patients enrolled, of whom 33 were response-evaluable. With 20 + 13 = 33 response-evaluable patients, the revised inferential error rates were: type I error of 0.03 and power of 0.67. After completing the revised stage 2, at least 19 responders were needed to conclude that the true, unknown response rate was at least 0.60. Exact, minimum-width 90% confidence intervals (CIs) for response and toxicity rates were calculated using the Casella method [11] , as implemented in StatXact software [12] . Standard KaplanMeier estimates of the censored response duration and survivorship functions were computed. Owing to the small sample sizes, survival statistics (e.g. median) were estimated more conservatively using linear interpolation [13] between successive event times on the Kaplan-Meier curves. Table 1 . Twenty-two patients had adenocarcinoma and 13 had squamous cell cancer. Of these 35 patients, 10 (29%) had cancer of the gastroesophageal junction. Fifteen patients (43%) had non-metastatic esophageal cancer. Twenty patients had metastatic disease at study entry with a median of two sites involved, liver (eight), celiac nodes (15) and lung (three) being most common. No patient had received prior chemotherapy or radiation for esophageal cancer.
Results
Thirty
Treatment administration
Two patients refused chemotherapy after registration and were not treated on study. A total of 166 cycles were administered to the remaining 33 patients, with a median of five cycles per patient (range 1 or 2 to 12). Fifteen patients (45%) required dose reductions. Thirteen required a dose reduction of only one dose level. Dose escalation was feasible in six patients. Eight patients with non-metastatic disease with either stable or responding disease underwent subsequent local therapy after a median of 3.5 cycles (range one to six) of chemotherapy. Four patients received chemoradiation consisting of 5060 cGy of radiation and either two cycles of cisplatin/5-fluorouracil (5-FU) (one patient) or infusional 5-FU (three patients). One patient had radiation therapy only. One patient was treated with cisplatin and 5-FU with concurrent radia-tion (5040 cGy) followed by surgery. One patient had surgery only, and the last patient had surgery followed by radiation therapy.
Response and survival
Fifteen of the 35 (43%; 90% CI 0.30-0.58) registered patients had a partial response. Among the 33 response-evaluable patients, the partial response rate was 45% (90% CI 0.31-0.61). With only 15 responders among 33 response-evaluable patients, we concluded that the sample response proportion (15/33 = 45%) better supported the null hypothesis that the true unknown response rate was at most 0.40. Response rates were not statistically significantly different in the patients with adenocarcinoma versus squamous cell histology (50% versus 31%, respectively), non-metastatic versus metastatic disease (33% versus 50%, respectively), or in patients with gastroesophageal junction cancer versus midesophageal cancer (70% versus 32%, respectively). For the 15 partial responders, the median response duration was 2.8 months (90% CI 2.1-5.4). The Kaplan-Meier estimate of the response duration curve for these 15 patients is given in Figure 1 . The 6-month relapse-free survival was 22% (90% CI 0.03-0.41). Two patients were still in partial remission at the time of surgery for a censoring rate of two of 15 (13%). In the 15 responders, 12 of 13 relapses occurred within 7 months of completion of chemotherapy. The remaining relapse occurred at 15.2 months.
The overall median survival was 9 months (90% CI 7-13.8). The Kaplan-Meier estimate of survival for the 35 eligible patients is given in Figure 2 . The 1-and 2-year survival rates were 43% (90% CI 0.29-0.57) and 17% (90% CI 0.07-0.28), respectively. Among the expired patients the longest survival was 35.2 months. Five patients are still alive, for a censoring rate of 14%.
In the 15 patients with non-metastatic disease, the response rate was 33% (90% CI 0.15-0.58). Four patients with non-metastatic disease are still alive and in remission, with a median follow-up of 41 months. Of these four patients, two underwent chemoradiotherapy, and three underwent surgery after initial treatment with Supra-clavicular 1 carboplatin and paclitaxel. There were 27 patients who were not treated with curative intent: the 20 metastatic disease patients plus the seven patients with non-metastatic disease who did not achieve at least stable disease. For these 27 patients, the median time to progression was 3.4 months (90% CI 2.3-4.2) (Figure 3 ) and median overall survival was 8.8 months (90% CI 6.1-13.8) (Figure 4 ).
Toxicity
The treatment was generally well tolerated in the outpatient setting. Thirty-three treated patients were evaluable for toxicity.
The most common grade 3-4 toxicity was neutropenia (52%). Table 2 summarizes the other common toxicities. No treatmentrelated deaths were reported. Nine patients required hospitalization, three for dehydration, two for neutropenic fever, two for infection and one for blood transfusion. One patient with locally advanced disease was lost to follow-up after two cycles, having experienced a partial remission. This patient had a history of alcoholic cardiomyopathy and died of congestive heart failure 4 months from study entry. No increased toxicity was seen in the patients with locally advanced disease who subsequently received local therapy.
Discussion
The outcome of patients with metastatic esophageal cancer remains poor. Of the cisplatin-based chemotherapy regimens, cisplatin and 5-FU remains the most commonly used combination. Response rates reported in patients with metastatic disease with this combination are 30-35%, and median survival is 8-9.5 months [2, 14] . Toxicity with such a combination can be significant, and includes myelosuppression, gastrointestinal toxicity, cerebrovascular accidents and myocardial injury [14] . Furthermore, the regimen of continuous infusion 5-FU makes administration in an outpatient setting less convenient. Trials evaluating the addition of other chemotherapeutic agents such as etoposide [3, 15] , interferon-α [16] and folinic acid [17] to cisplatin and 5-FU have resulted in only minor improvements in response rates, without any impact on survival. Paclitaxel has demonstrated significant single-agent activity in esophageal cancer, with response rates of 32% [4] . The rationale for combining paclitaxel with platinum compounds is the synergy between paclitaxel and cisplatin in the preclinical models [5] . Encouraged by these findings, a phase II trial of paclitaxel added to cisplatin and 5-FU in metastatic esophageal carcinoma was conducted [18] . Although the response rate of 48% was a potential improvement over historical controls, the frequency of grade 3-4 toxicities was significant. Hospitalizations were required in 48% of the patients due to gastrointestinal and hematological toxicity. A subsequent phase II trial evaluated a 24-h infusion paclitaxel with cisplatin in patients with metastatic esophageal cancer [19] . The response rate was 44%, but toxicity remained significant. Hospitalization was required in half of the patients. Of even more concern was the 11% treatment-related mortality secondary to cardiac toxicity, stroke or cardiac arrhythmias. In our study the objective response rate and median survival with carboplatin and paclitaxel were 43% and 9 months, respectively, which are comparable to the reported response rates with cisplatin-based regimens. However, this outpatient-based regimen was easier to administer and was better tolerated, with fewer sideeffects and hospitalization, which were required in 25% of the patients [19] . Non-metastatic esophageal cancer is potentially curable in a proportion of patients through multimodality treatment involving chemoradiotherapy [20] . Both distant metastases and local relapses remain a major cause of mortality in patients treated with conventional systemic therapies such as 5-FU and cisplatin. Clinical trials aimed at introducing more active agents and combinations for systemic treatment in localized disease are ongoing. Paclitaxel, for example, is being developed in combination with a platinum compound administered concurrently with radiation therapy [21] , as part of an induction therapy [22] prior to either chemoradiotherapy or surgery, or in the adjuvant setting [23] . The induction chemotherapy approach followed by chemoradiotherapy offers the advantage of evaluating the efficacy of drug combinations in early disease as well as allowing patients to receive conventional therapy. In our study, carboplatin and paclitaxel administration prior to localized therapy was feasible without increased toxicity of the local treatments. It is uncertain, however, whether response to induction chemotherapy would further decrease the risk of local or distant relapse following local treatment. After a relatively long follow-up of 41 months, 27% of patients with non-metastatic disease in this trial were free of any evidence of relapse. In a recently reported phase II trial of induction carboplatin and paclitaxel prior to esophagectomy, major clinical responses and resectability were achieved in 61% and 77% of the patients, respectively [22] . Complete pathologic response was seen in 12% of the patients, but that was less than would be expected with concurrent chemoradiotherapy. However, when considering that a systemic treatment efficacy is a primary motive with induction chemotherapy, frequent clinical and complete pathologic responses may indicate control of micrometastatic disease. A recently reported phase II trial evaluated adjuvant cisplatin and paclitaxel in 59 patients with resected esophageal and gastroesophageal junction tumors. The regimen appeared to be active, with a 2-year survival rate of 60%. Grade 3 or 4 toxicities were observed in 56% of the patients. Eventually, randomized trails will be needed to evaluate the role of taxanebased adjuvant or neo-adjuvant chemotherapy in localized esophageal cancer.
In conclusion, the carboplatin and paclitaxel combination is a reasonable treatment for patients with metastatic esophageal cancer due to the improved toxicity profile as compared with other cisplatin-based regimens. Future trials focusing on the integration of novel targeted therapies such as epidermal growth factor receptor blockers or cyclooxygenase-2 inhibitors with conventional chemotherapy might further improve systemic efficacy in patients with this disease. Given the moderate activity and safety profile of carboplatin and paclitaxel, we believe this combination would be a reasonable chemotherapy regimen for these investigations.
